Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study
Baricitinib 2 mg in RA patients with moderate renal dysfunction showed comparable efficacy and retention rate to 4 mg in patients with normal/mild renal dysfunction. The incidence and types of adverse events were consistent with previous studies, indicating the safety of the drug at these dosages.
Authors
- Yasuharu Nakashima (ORCID: https://orcid.org/0000-0002-6692-982X)
- Ryuji Nagamine (ORCID: https://orcid.org/0000-0003-3865-7684)
- Eisuke Shono
- Masakazu Kondo (ORCID: https://orcid.org/0000-0003-1381-7549)
- Yasushi Inoue (ORCID: https://orcid.org/0000-0002-8313-3591)
- Yutaro Yamasaki
- Hiroaki Niiro (ORCID: https://orcid.org/0000-0003-0914-9066)
- Akira Maeyama (ORCID: https://orcid.org/0000-0002-3142-7889)
- Hiroshi Harada (ORCID: https://orcid.org/0009-0005-0149-9434)
- Munetoshi Nakashima
- Takuaki Yamamoto
- Tomomi Tsuru
Institutions
- Kyushu University (JP)
- Fukuoka University (JP)
- Kurume University Medical Center (JP)
- Japanese Red Cross Fukuoka Hospital (JP)
- Ono Clinic (JP)
- Nishijin Hospital (JP)
- Tsurugi Hospital (JP)
Publication Details
- Journal
- BMC Rheumatology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s41927-024-00446-y
- Citations
- 4
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.88